Immunotherapy of hepatocellular carcinoma;Immuntherapie des hepatozellulären karzinoms

Deutsche Medizinische Wochenschrift

Volumn 126, Issue 51-52, 2001, Pages 1464-1466

  Geissler, M ^a   Mohr, L ^a   Blum, H E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE; COMPLEMENTARY DNA; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; DENDRITIC CELL; GENE THERAPY; HUMAN; IMMUNOTHERAPY; LIVER CELL CARCINOMA; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CYTOKINES; DENDRITIC CELLS; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS;

EID: 0035930881     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-19215     Document Type: Review

References (8)

1. Gene therapy for hepatocellular carcinoma
2. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein
3. Immunotherapy directed against alpha fetoprotein results in autoimmune liver disease during liver regeneration in mice
4. Mouse α-fetoprotein-specific DNA-Based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice
5. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice
6. Tolerance, danger and the extended family
7. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma
8. Dendritic cell-based immunotherapy of cancer